PHS
NAGE

Pekin Hardy Strauss’s Niagen Bioscience NAGE Stock Holding History

Pekin Hardy Strauss’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-35,000
Closed -$150K – 199
2017
Q3 		$150K Buy
+35,000
New +$128K 0.03% 180

Other funds holding NAGE

IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Pekin Hardy Strauss's NAGE Position: Q4 2017 in Review

Pekin Hardy Strauss sold out of Niagen Bioscience (NAGE) in Q4 2017, closing a stake of 35,000 shares — an estimated $150K sold.

Pekin Hardy Strauss first reported a position in NAGE in Q3 2017 and held it in 1 quarter. The position peaked at $150K in Q3 2017. 53 funds tracked by Wall St. Rank hold NAGE as of Q4 2017.

  • Pekin Hardy Strauss reported no remaining Niagen Bioscience position as of Q4 2017 after selling out during the quarter.
  • Pekin Hardy Strauss sold 35,000 Niagen Bioscience shares in Q4 2017, an estimated $150K.
  • Pekin Hardy Strauss first reported a position in Niagen Bioscience in Q3 2017 and held it in 1 quarter.
  • Pekin Hardy Strauss's Niagen Bioscience position peaked at $150K in Q3 2017.
  • 53 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2017.

Based on Pekin Hardy Strauss's 13F filing for Q4 2017, filed 2 Feb 2018.